Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis

Although currently available immune checkpoint inhibitors with similar but slightly different indications are recommended for patients with advanced non-small cell lung cancer (NSCLC), their effects by programmed death-ligand-1 (PD-L1) expression level are not yet known. This meta-analysis aims to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jinchul, Cho, Jinhyun, Lee, Moon Hee, Lim, Joo Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078964/
https://www.ncbi.nlm.nih.gov/pubmed/30082893
http://dx.doi.org/10.1038/s41598-018-30277-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078964/
https://www.ncbi.nlm.nih.gov/pubmed/30082893
http://dx.doi.org/10.1038/s41598-018-30277-0

Ejemplares similares